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Epithelial ovarian carcinoma is the leading cause of death from
gynaecological malignancies in the great majority of developed
countries (Nakashima et al, 1990). This high mortality is consid-
ered to be, in large part, due to the advanced stage of the disease
commonly present at the time of diagnosis, but many clinical
studies have reported that there are some prognostic factors in
ovarian carcinoma other than clinical stages, such as histology,
the degree of primary surgical cytoreduction, response to
chemotherapy, and others (Young et al, 1978; Redman et al, 1986;
Heintz et al, 1986; Piver et al, 1988; Omura et al, 1991; Del
Campo et al, 1994).
Sex steroid hormones have been implicated in the aetiology
and/or progression of some epithelial ovarian cancers. Both pro-
gesterone (PR) and oestrogen receptors (ER) have been reported in
human epithelial ovarian carcinoma (Rao and Slotman, 1991). In
endometrioid endometrial and breast carcinoma, steroid hormone
receptor status correlates well with response to hormonal manipu-
lation and prognosis (McGuire et al, 1978; Benraad et al, 1980;
Bloom et al, 1980; Osborne et al, 1980; Ehrlich et al, 1981;
Kaupilla, 1984). However, in epithelial ovarian carcinoma, the
prognostic significance of tumour ER and PR status among
patients still remains controversial (Bizzi et al, 1988; Masood et al,
1989; Sevelda et al, 1990; Rao and Slotman, 1991; Hempling et al,
1998).
PR is a member of a subgroup of nuclear receptors which regu-
late a number of physiological and morphological processes in
response to binding of their ligands (Evans, 1988). There are two
isoforms of the human PR, PRA and PRB, which differ only in
that the smaller isoform, PRA, lacks the N-terminal 164 amino
acids of the larger isoform, PR-B (Horwitz and Alexander, 1983;
Jeltsch et al, 1986; Savouret et al, 1990; Kastner et al, 1990). PRA
and PRB are products of a single gene and are translated from an
individual messenger RNA species under the control of distinct
promoters (Kastner et al, 1990). The transcription of both isoforms
is indirectly induced by oestradiol via ER (Kastner et al, 1990).
Both PRA and PRB function as ligand-activated transcription
factors but several in vitro studies have demonstrated different
functional characteristics between these two isoforms. For
instance, transcriptional activation of the progesterone responsive
element-containing promoters by PRB is more marked than that
by PRA, although the differences are cell-specific (Kastner et al,
1990; Wen et al, 1994; Giangrande et al, 1997). In addition, PRA
can also act as a transcriptional inhibitor of other steroid hormone
receptors, including ER and PRB (Wen et al, 1994; Giangrande et
al, 1997; Vegeto et al, 1993; Kraus et al, 1995). Results of these
studies indicate that the relative levels of PRA and PRB within
target cells may determine the nature and functional responses to
progesterone.
In the normal human endometrium (Mote et al, 1999; Critchley
et al, 1998; Mangal et al, 1997; Wang et al, 1998), leiomyoma
(Viville et al, 1997; Fujimoto et al, 1998) and endometrial carci-
noma (Kumar et al, 1998; Fujimoto et al, 1995) several studies
have examined the relative abundance of PRA and PRB expres-
sion, and all studies to date support the presence of distinct path-
ways of progesterone actions in these tissues. However, the
expression of PRA and PRB in epithelial ovarian cancer and their
clinical significance have not been examined. Therefore, in this
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study, we evaluated the expression of PRA and PRB in human
epithelial ovarian carcinoma using immunohistochemistry and RT-
PCR, and their significance as prognostic indicators in epithelial
ovarian cancer. We also evaluated the relationship between PR
isoforms and ER-α immunohistochemically, because of the unique
in vitro activation–inhibition interactions of these sex steroid
receptors described above.
MATERIALS AND METHODS
We studied a total of 107 cases of common epithelial ovarian
carcinoma. The clinicopathological features of the patients exam-
ined are summarized in Table 1. Information regarding age,
performance status on admission, histology, stage, grade, residual
tumour after primary surgery, response to primary chemotherapy,
and overall survival was retrieved from the review of patient
charts. Median follow-up time of the patients in this study was 54
months (18–112 months). Seventy-seven patients (71.9%) were
optimally cytoreduced at the time of surgery. The great majority of
patients (83.2%) received platinum-containing chemotherapy, and
approximately half of them (49.4%) received chemotherapy
consisting of cisplatin, adriamycin and cyclophosphamide (CAP).
Moreover, more than half of the patients (62.5%) who had measur-
able disease after primary surgery responded to chemotherapy. It
was difficult to evaluate the response to primary chemotherapy in
relation to survival because 75 of the 107 patients (72.0%) were
optimally cytoreduced with primary surgery, and thus they could
not be evaluated (NE) on their response to chemotherapy.
Performance status was defined according to WHO criteria (World
Health Organization, 1979). Histology, stage and grade were
determined according to FIGO criteria (International Federation of
Gynecology and Obstetrics, 1987; Pettersson, 1994). Residual
disease was determined by the amount of unresectable tumour left
following primary cytoreductive surgery. Optimal cytoreduction
was defined as no gross residual tumour greater than 2 cm in diam-
eter, whereas suboptimal cytoreduction was defined as any gross
residual disease remaining greater than 2 cm in diameter.
Response to primary chemotherapy was assessed according to
WHO criteria (World Health Organization, 1979). Overall survival
was calculated from the time of initial surgery to death, or the date
of last contact. Survival times of patients still alive or lost to
follow up were censored in February 2000. All of these archival
specimens were retrieved from the surgical pathology files at
Tohoku University Hospital, Sendai, and Miyagi Prefectural
Cancer Center, Natori, Japan. These specimens were all fixed in
10% formalin and embedded in paraffin. Among these 107 cases,
16 cases were available for examination by reverse transcription-
polymerase chain reaction (RT-PCR) analysis. These specimens
were dissected immediately into small pieces following gross
dissection, quickly transferred to liquid nitrogen, and then stored
at –80° C until further use. The research protocol was approved by
the ethics committee of Tohoku University School of Medicine,
Sendai, Japan.
Immunohistochemistry
Immunohistochemical analysis was performed using the strepta-
vidin–biotin amplification method using a Histofine Kit (Nichirei,
Tokyo, Japan), and have been previously described in detail
(Hirasawa et al, 1997). The characteristics of the primary anti-
bodies employed in this study are summarized in Table 2. The
hPRa2 and hPRa3 antibodies recognize PRB and PRA and B,
respectively. The hPRa7 antibody employed in this study recog-
nizes both PRA and PRB on immunoblot analysis (Clarke et al,
Table 1 Correlations between clinical characteristics and hormone receptor immunoreactivity
Median labelling indices (range)
n PRAB PRA PRB ERb
Totala 107 42.4 (0–100) 2.4 (0–58.4) 43.6 (0–93.2) 12.8 (0–85.2)
Age
< 50 years 47 44 (0–100) 4 (0–58.4) 47.2 (0–92) 12.8 (0–85.2)
≥ 50 years 60 41.6 (0–96) 2.2 (0–48) 40.2 (0–93.2) 12.4 (0–63.6)
Performance status
0–1 76 47.6 (0–100) 2.7 (0–58.4) 45.6 (0–93.2) 16.2 (0–85.2)
2–4 31 30 (0–90) 0 (0–35.2) 25.2 (0–90) 4 (0–63.6)
Histology
Serous 46 52.8 (0–100) 2.4 (0–43.2) 51.2 (0–93.2) 22.4 (0–85.2)
Endometrioid 18 40 (0–82) 0 (0–52) 39.2 (0–75.6) 0 (0–49.6)
Clear cell 25 32.4 (0–94) 0 (0–35.2) 31.2 (0–92) 8.8 (0–54)
Mucinous 18 55.8 (0–100) 7.4 (0–58.4) 39.7 (0–82) 23.4 (0–67.2)
Stage
I–II 50 47.4 (0–100) 3 (0–58.4) 43.2 (0–92) 16.2 (0–67.2)
III–IV 57 34 (0–100) 2.4 (0–52) 43.6 (0–93.2) 10.4 (0–85.2)
Grade
1 44 51.2 (0–100) 2.6 (0–52) 43.6 (0–92) 8.8 (0–68)
2 40 42.4 (0–100) 2.4 (0–58.4) 43.6 (0–90) 14.2 (0–54)
3 23 39.8 (0–96) 0 (0–35.2) 38.8 (0–93.2) 14 (0–85.2)
Residual tumour
Optimal 77 48 (0–100) 4 (0–58.4) 45.6 (0–92) 14.8 (0–85.2)
Suboptimal 29 27.4 (0–96) 0 (0–31.2) 24 (0–93.2) 4.4 (0–59.2)
aDifference of total labelling indices (LI) between PRA and PRB is significant (P < 0.01); bSignificant difference of LIs was observed for performance status and
histology (P < 0.05); Performance status score: 0 = asymptomatic and fully active; 1 = symptomatic, fully ambulatory, restricted in physically strenuous activity;
2 = symptomatic, ambulatory, capable of self-care, more than 50% of waking hours are spent out of bed; 3 = symptomatic, limited self-care, spends more than
50% of time in bed, but not bedridden; 4 = completely disabled, no self-care, bedridden1490 J Akahira et al
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1987), but specifically recognizes PRA when utilized for immuno-
histochemistry (Mote et al, 1999). The ER antibody recognizes
ER-α , the traditinal estrogen receptor, but not ER-β . The
antigen–antibody complex was visualized with 3,3′ -diaminobenzi-
dine (DAB) solution (1 mM DAB, 50 mM Tris-HCl buffer, pH
7.6, and 0.006% H2O2), and counterstained with haematoxylin.
Proliferative-phase endometrial glands were used as positive
controls for PR isoforms and ER-α (Clarke et al, 1987). As nega-
tive controls, 0.01 M phosphate buffered saline and normal mouse
IgG were used in place of primary antibodies. No specific
immunoreactivity was detected in these tissue sections.
Scoring of immunostaining
For evaluation of PRA, PRB, PRAB and ER-α immunoreactivity,
labeling index (LI) was obtained in carcinoma cells as described
by Sasano et al (1996). We obtained LI in the following manner.
Two of the authors (JA and TM) independently evaluated at least
500 carcinoma cells microscopically. These fields of evaluation
were determined by these two authors prior to evaluation using
double-headed light microscopy. The mean value was obtained
when interobserver differences were less than 5%. Immunostained
slides were simultaneously evaluated using double-headed light
microscopy when interobserver differences were greater than 5%.
Intraobserver differences were less than 5% in this study.
RT-PCR
Total RNA was extracted by homogenizing tissue specimens in
guanidinium thiocyanate followed by ultracentrifugation in
caesium chloride, as described previously (Sambrook et al,
7.1–7.87), and quantified spectrophotometrically at 260 nm. An
RT-PCR kit (SUPERSCRIPT Preamplification system, Gibco-
BRL, Grand Island NY, USA) was employed in the synthesis and
amplification of cDNA. cDNAs were synthesized from 5 µ g of
total RNA using oligo (dT) primer and reverse transcription was
carried out for 50 min at 42° C with SUPERSCRIPT II reverse
transcriptase. After an initial 1 min denaturation step at 94° C, 35-
cycle PCRs were carried out on a DNA thermal cycler (PTC-200
DNA Engine, MJ Research Inc, USA) under the following condi-
tions: 1 min denaturation at 94° C, 1 min annealing at 56° C, and a
2 min extension at 72° C. Primers for PCR reactions were as
follows; PRB (Kumar et al, 1998): 5′ sense-ACAGAATTCAT-
GACTGAGCTGAAGGCAAAGGGT and 3′ antisense-ACAA-
GATCTCAAACAGGCACCAAGAGCTGCTGA (744–1173, 429
bp); PRAB (Kumar et al, 1998): 5′ sense-ACAGAATTCA
TGAGCCGGTCCGGGTGCAAG and 3′ antisense-ACAA-
GATCTCCACCCAGAGCCCGAGGT TT (1239–1482, 243 bp);
β -actin (Willey et al, 1998): 5′ sense-GATTCCTATGTGGGC-
GACGAG and 3′ antisense-CCATCTCTTGCTCGAAGTCC
(192–723, 532 bp). β -actin primers were utilized as positive
controls. Negative controls without RNA and without reverse tran-
scriptase were also performed.
Statistical analysis
Statistical analysis was performed using Stat View 5.0 (SAS
Institute Inc, North Carolina, USA) software. The statistical signif-
icance of association between hormone-receptor status and charac-
teristics of the patients was evaluated using a Mann–Whitney
U-test, Kruskal–Wallis, and Scheffe analysis. Correlation among
scored PR isoforms and ER-α immunohistochemistry was also
assessed using a Spearman rank correlation. Univariate analysis of
prognostic significance for prognostic factors was performed using
a log-rank test, after each survival curve was obtained by the
Kaplan–Meier method. Multivariate analysis of survival time was
performed with Cox’s proportional hazards model. All patients
who could be assessed were included in the intention-to-treat
analysis. A result was considered significant when the P value was
less than 0.05.
RESULTS
Results of immunohistochemistry are summarized in Table 1.
Immunoreactivity for PR isoforms and ER-α were confined exclu-
sively to the nuclei of tumour cells. No immunoreactivity,
however, was detected in stromal cells (Figure 1). Median LI for
PRB was 43.2% (range 0–93.2%), while that of PRA was 2.4%
(0–58.4%). In all histological types and age groups, PRB LI was
significantly higher than PRA LI (P < 0.01). No significant corre-
lations were detected between PRAB, PRA or PRB LI and any of
the clinicopathological parameters in the patients examined in this
study. There was a highly significant correlation between ER-α
and PRB LI (rs = 0.60, P < 0.0001), and a weak correlation was
also detected between ER-α and PRA LI (rs = 0.28, P = 0.038,
Figure 2).
Results of univariate analysis of prognostic significance for
each variable, with respect to survival, are summarized in Table 3.
In this analysis, we determined the positive cases as those with an
LI of more than 10%. There were 35.5% and 71.9% PRA- and
PRB-positive cases, respectively. Among the clinicopathological
factors examined, those significantly associated with overall
survival were histology, stage, performance status, residual
tumour, PRAB, PRB, and ER-α immunoreactivity. In multivariate
Table 2 Primary antibodies employed in immunohistochemistry
Antibody Source Optimal dilution Antibody
retrieval
PRA and B: hPRa3 (Monoclonal) Neomarkers (California, USA) 1:50 Autoclavea
PR A: hPRa7 (Monoclonal) Neomarkers (California, USA) 1:100 Autoclavea
PRB: hPRa2 (Monoclonal) Neomarkers (California, USA) 1:100 Autoclavea
ER α (Monoclonal) Immunotech (Marseille, France 1:5 Autoclavea
aHeat in an autoclave for 5 min in citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0)analysis, PRB immunoreactivity was a significant (P = 0.037)
predictor of overall survival but not PRAB or ER-α (Table 4,
Figure 3). Performance status, stage, and residual tumour all
turned out to be independent prognostic factors. Results of RT-
PCR analysis for each histologic subtype are summarized in
Figure 4. The expression of the mRNAs for PRAB and PRB are:
serous, 4/5 and 3/5; mucinous, 3/3 and 3/3; endometrioid, 2/3 and
Progesterone receptors A and B in ovarian cancer 1491
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A B
Figure 1 Immunohistochemistry for (A) PRAB and (B) PRB in ovarian serous adenocarcinoma obtained from a 47-year-old patient, stage IIIc. Marked nuclear
immunoreactivity was detected for PRAB (A) and PRB (B) in this case (magnification × 200)
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Figure 2 Correlation between (A) PRA and (B) PRB labeling index (LI) and ERα LI in ovarian cancers. Both PR isoforms and ER-α LI were compared by the
Spearman rank correlation test. Several points in the Figures (A and B) overlap each other because of the same values
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Figure 3 Correlation between PRB labelling index (LI) and survival of
patients with epithelial ovarian carcinoma. PRB LI was determined as
described in the ‘Materials and Methods’. Kaplan–Meier curves were
compared
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Figure 4 RT-PCR analysis of total RNA extracted from ovarian epithelial
carcinoma cases. Bands of the correct size for PRAB (243 bp) and PRB
(429 bp) were detected in each histological subtype of ovarian epithelial
carcinoma (Lanes 1–5 = serous: lanes 6–8 = mucinous; lanes
9–11 = endometrioid; lanes 12–16 = clear cell). Positive (β -actin) and
negative (N) controls are also shown.1492 J Akahira et al
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2/3; clear cell, 4/5 and 3/5, respectively. The positivities of RT-
PCR analysis in each case of ovarian carcinoma were consistent
with those of immunohistochemistry.
DISCUSSION
Human epithelial ovarian carcinoma is believed to be a sex steroid
hormone-dependent neoplasm, but the biological significance of
PR, especially its role in growth regulation, and its correlation to
clinical outcome in patients, has remained in dispute. Several
groups of investigators reported no significant difference in the
survival of ovarian cancer patients with respect to PR levels (Bizzi
et al, 1988; Geisler et al, 1996; Masood et al, 1989), while some
other studies have reported that a higher PR status correlated well
with increased survival (Inversen et al, 1986; Masood et al, 1989;
Slotman et al, 1989; Kommoss et al, 1992; Hempling et al, 1998;
Langdon et al, 1998). Review of these reports indicates that the
difference in these studies may be due to the heterologous compo-
sition of the patient population. For example, several groups of
investigators included tumours of low malignant potential and
others included only cases with advanced stage of cancer (Masood
et al, 1989; Geisler et al, 1996; Hempling et al, 1998). Hempling et
al (1998) and Inversen et al (1986) both demonstrated PR as a
significant prognostic factor following multivariate analysis, but
both examined only advanced (stage III–IV) epithelial ovarian
carcinoma. Therefore, in this study we evaluated only epithelial
ovarian carcinoma without low malignant potential, in all stages
and all major histologic subtypes using a multivariate analysis.
The identification of PR subtypes demonstrates that the analysis
of subtypes for PR can provide new insights into the biological
roles of PR in human epithelial ovarian carcinoma. In our study,
PRB is dominantly expressed in all types or groups of epithelial
ovarian carcinoma using both immunohistochemistry and RT-
PCR. In addition, PRB, but not PRAB, immunoreactivity turned
out to be an independent prognostic factor following multivariate
analysis. In all previous studies on PR in ovarian epithelial carci-
noma, PR isoforms were not evaluated separately as in PRAB in
our present study. Therefore, the discrepancy between the results
of previous studies and our present examination may be due to the
evaluation of PR subtype in our study, and the analysis of PR
isoforms considered important in the evaluation of the survival of
patients diagnosed with epithelial ovarian carcinoma. Fujimoto et
al (1995) reported the expression of PR isoform mRNAs in
ovarian carcinoma using RT-PCR. In their study, six out of ten
cases expressed only PRB mRNA. They subsequently concluded
that the dominancy of PRB mRNA expression was associated with
the advanced clinical stage of ovarian cancer (Fujimoto et al,
1995). Results of their study, especially the dominance of PRB, but
not PRA mRNA, were consistent with those of our present study
(Fujimoto et al, 1995). Therefore, the dominant expression of PRB
is considered to be a characteristic feature of ovarian cancer, in
contrast to breast and endometrial carcinoma, in which PRA is the
dominant subtype of PR (Kumar et al, 1998; Graham et al, 1996).
The biological role of progesterone in epithelial ovarian carci-
noma is unknown, but progesterone is, in general, considered to
function antagonistically to oestrogen-mediated cell proliferation
(Clarke and Sutherland, 1990). PRA has been reported to be a tran-
scriptional inhibitor of ER (Simpson et al, 1998), and PRB has the
ability to up-regulate the transcription of genes required for cell
differentiation (Kumar et al, 1998). The transcriptional activation
of PRB is more marked than PRA (Kastner et al, 1990), which
Table 3 Univariate analysis of overall survival
Factor n Median P
survival (months)
Age
< 50 years 47 > 60 0.9
≥ 50 years 60 56
Performance status
0–1 76 > 60 < 0.0001
2–4 31 22
Histology
Serous 46 60 0.0375a
Endometrioid 18 37
Mucinous 18 > 60
Clear cell 25 > 60
Stage
I–II 50 > 60 < 0.0001
III–IV 57 38
Grade
1 44 > 60 0.504
24 0 5 1
32 3 3 5
Residual disease after primary surgery
Optimal 77 > 60 < 0.0001
Suboptimal 29 19
PRAB LI
Negative 28 40 0.0207
Positive 79 > 60
PRA LI
Negative 69 > 60 0.24
Positive 38 > 60
PRB LI
Negative 30 37 0.0117
Positive 77 > 60
ER-α LI
Negative 51 52 0.0374
Positive 56 > 60
aSignificant difference was observed for endometrioid vs mucinous
adenocarcinoma; positive immunoreactivity was defined as LI > 10
Table 4 Multivariate analysis of survival time using Cox’s proportional
hazards model
Covariate Relative risk 95% CIa P
Performance status
0–1 1.000
2–4 2.907 1.242–6.803 0.0138
Histology
Serous 1.000
Endometrioid 2.162 0.821–5.698 0.119
Clear cell 1.659 0.655–3.788 0.177
Mucinous 0.423 0.044–4.082 0.457
Stage
I–II 1.000
III–IV 2.565 1.252–10.222 0.028
Residual disease after primary surgery
Optimal 1.000
Suboptimal 5.150 2.000–13.333 <0.001
PRAB LI
Negative 1.000
Positive 0.210 0.039–1.126 0.069
PRB LI
Negative 1.000
Positive 0.173 0.0333–0.901 0.037
ER LI
Negative 1.000
Positive 0.878 0.316–2.440 0.802
aCI = confidence intervalProgesterone receptors A and B in ovarian cancer 1493
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suggests that the inhibitory effects on cell proliferation by
progesterone is, at least, initially mediated through PRB.
Friedlander et al (1989) described a significantly lower S-phase
fraction among PR-positive tumours compared with PR-negative
tumours. Additionally, they demonstrated that a significantly
greater proportion of diploid tumors were PR-positive than were
aneuploid tumours (Friedlander et al, 1989). Both tumour ploidy
and proliferative activity, determined by S-phase fraction, have
been demonstrated to be significant determinants in the survival of
patients with epithelial ovarian cancer (Erhardt et al, 1984; Volm
et al, 1985). Therefore, ovarian epithelial carcinoma cases associ-
ated with functional PR, especially PRB, and sufficient in situ
availability of progesterone are considered to be associated with
better clinical outcome. This may be due to the inhibitory actions
of progesterone on tumour cell proliferation, but this hypothesis
awaits further investigation for clarification. Kumar et al (1998)
examined the expression of PRA and PRB in endometrial carci-
noma and reported that selective down-regulation of PRB may
represent an insufficient response to progestin therapy in patients
with poorly differentiated endometrial carcinoma (Kumar et al,
1998). Similar results were also reported in breast carcinoma, i.e.
tumours containing primarily PRA related to poor response to
endocrine agents (Geisler et al, 1996). These studies have demon-
strated that the dominant expression of PRB suggests a good
response for progestin in breast and endometrial cancer patients,
although the clinical usefulness of sex steroid hormones in the
treatment of ovarian cancer has yet to be determined (Ahlgren
et al, 1993).
There was, in general, a good correlation between ER-α and PR
in epithelial ovarian carcinoma, suggesting that the regulation of
PR, especially of PRB, may be under oestrogen control in ovarian
epithelial carcinoma, consistent with the results of previous in
vitro studies (Kastner et al, 1990; Savouret et al, 1990). Both PRA
and PRB mRNAs have been demonstrated to be increased by
oestrogen, but between these two isoforms, preferential up-regula-
tion of PRB by oestrogen has been reported in the T47D human
breast carcinoma cell line (Graham et al, 1995), and in human
endometrial tissue (Mangal et al, 1997). However, it has also been
reported that the stimulatory effects of oestrogen on PRA protein
levels were greater than PRB in chicken oviduct (Syvala et al,
1997), suggesting that oestrogen stimulation of PRA and PRB is
likely to be cell-, tissue-, and species-specific. In addition, mecha-
nisms other than those under ER control can influence PR expres-
sion, as was demonstrated in PR-positive, ER-negative breast
tumours (Horwitz, 1981). PR expression has been demonstrated to
be regulated by growth factors (Katzenellenbogen and Norman,
1990), and ER-α knockout mice continue to express a low level of
PR mRNA (Shughrue et al, 1997). Therefore, further investiga-
tions are required to clarify the possible mechanisms of regulation
of PRA and PRB in human epithelial ovarian carcinoma.
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